NEW YORK (GenomeWeb News) – Qiagen reported after the close of the market on Monday that its first-quarter revenues rose 7 percent while its net income jumped around 22 percent year over year.

The Hilden, Germany-based molecular diagnostics and sample preparation technologies firm reported total sales of $220.9 million for the three months ended March 31, compared to sales of $207.1 million for the first quarter of 2008. Foreign currency translation had a negative 9 percent effect on the first-quarter results while acquisitions added 5 percent to its revenue growth.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.